The liver plays a central role in the transformation and degradation of endogenous and exogenous chemicals, and in the removal of unwanted cells such as damaged, genetically mutated and virus-infected cells. Because of this function, the liver is susceptible to toxicity caused by the products generated during these natural occurrences. Hepatocyte death is the major feature of liver injury. In response to liver injury, specific intracellular processes are initiated to maintain liver integrity. Inflammatory cytokines including tumor necrosis factor (TNF)a and interleukin-6 (IL-6) are key mediators of these processes and activate different cellular response such as proliferation, survival and death. TNFa induces specific signaling pathways in hepatocytes that lead to activation of either pro-survival mediators or effectors of cell death. Whereas activation of transcription factor NF-kB promotes survival, c-Jun N-terminal kinases (JNKs) and caspases are strategic effectors of cell death in the TNFa-mediated signaling pathway. This review summarizes recent advances in the mechanisms of TNFainduced hepatotoxicity and suggests that NF-kB plays a protective role against JNK-induced hepatocyte death. Identification of the mechanisms regulating interplay between the NF-kB and JNK pathways is required in the search for novel targets for the treatment of liver disease, including hepatitis and hepatocellular carcinoma.
Introduction
The liver is the principal tissue for metabolic clearing of exogenous chemicals (drugs) and endogenous chemicals such as cholesterol, steroid hormones, fatty acids, and proteins that would otherwise harm the body (Parkinson, 2001; Ioannides, 2008) . The liver turns both exogenous and endogenous chemicals into products that can be eliminated through the bile or urine. The inimitable role of the liver in the transformation and clearance of these substances also makes it susceptible to their toxic effects. Indeed, a number of these mechanisms can cause severe liver injury with consequent loss of liver function, ultimately affecting the body in many ways with important implications for the health of the entire organism (Antoine et al., 2008) .
A common consequence of livery injury is the death of hepatocytes, the major parenchyma cells that constitute this organ (Malhi and Gores, 2008) . Excessive hepatocyte death has been implicated in a wide range of liver diseases, including viral and alcoholic hepatitis, ischemia/ reperfusion (I/R) liver injury, and fulminant hepatic failure (Guicciardi and Gores, 2005) (Figure 1 ). Hepatocytes, however, are well equipped to face most challenges and possess an extraordinary ability to counteract the damaging effects of cytotoxic agents. This involves the activation of specific programs of gene expression that are capable of antagonizing the programmed cell death (PCD) pathways activated by many agents, resulting in hepatocyte survival and liver integrity (Wullaert et al., 2007; Sun and Karin, 2008) . When these programs fail, continued hepatocyte death can cause compensatory hepatocyte proliferation aimed at maintaining the overall liver mass, an event that promotes the development and progression of hepatocellular carcinoma (HCC; Figure 1 ) (Karin, 2006) . Indeed, it is becoming increasingly clear that when the balance between cell survival and cell death in the liver is tipped towards one outcome or the other, the road to liver disease is wide open (Wullaert et al., 2007) . Thus, a key question is how hepatocytes regulate the balance between survival and death to ensure tissue homeostasis.
An important role in the prevention of hepatocyte death is played by NF-kB transcription factors, which on activation can protect hepatocytes from apoptosis induced by tumor necrosis factor (TNF)a and other death-inducing signals through the expression and activation of critical genes encoding anti-apoptotic proteins (Dutta et al., 2006; Wullaert et al., 2007) . Mice deficient in components of the NF-kB pathway exhibit exacerbated hepatocyte apoptosis following TNFa stimulation both during embryonic development and in adults (Beg and Baltimore, 1996; Wullaert et al., 2007) . It was shown, however, that many of these anti-apoptotic proteins can only partially protect hepatocytes from death induced by TNFa when overexpressed in NF-kB-deficient cells, indicating the existence of other NF-kB-dependent protective mechanisms (Wang et al., 1998; Dutta et al., 2006; Wullaert et al., 2007) . Accumulating evidence has shown that at When the liver receives an insult, hepatocytes activate specific intracellular programs to induce PCD and proliferation. NF-kB plays an essential role in preventing TNFa-mediated hepatocyte death. In addition, NF-kB regulates important events that induce hepatocyte proliferation. Deregulation of these signaling pathways contributes to liver disease. Excessive hepatocyte death is associated with hepatitis and liver failure. Induction of hepatocyte PCD also promotes compensatory proliferation, which can lead to the development of HCC. least some of the cytoprotective effects of NF-kB in TNFa-induced hepatotoxicity are mediated by suppression of c-Jun N-terminal kinase (JNK) activity following TNFa challenge (Figure 2 ) Schwabe and Brenner, 2006; Wullaert et al., 2006) .
In addition to its beneficial function in protecting hepatocytes against TNFa-induced cytotoxicity, NF-kB activation might promote the survival of transformed hepatocytes, thus supporting malignancy and progression in cancer (Karin, 2006) . This dual role of NF-kB in hepatocytes emphasizes its intricate contribution to liver physiology and disease and highlights the need to study the molecular pathways that regulate the outcome of TNFa stimulation to understand how NF-kB can exert distinct functions in the liver. It is also evident that gaining insights into the molecular pathways that regulate hepatocyte fate in terms of survival or death is of therapeutic importance. This could, in fact, lead to the identification of novel therapeutic agents capable of preventing cell death during liver injury or malignant transformation. However, the mechanisms that regulate this balance are complex, cell-type specific and remain poorly understood.
In this review we summarize the mechanisms that have been proposed, especially in the context of TNFa-mediated liver injury, an important aspect in the pathogenesis of several human liver conditions including hepatitis and HCC. We focus on mechanisms behind the cross-talk between NF-kB-mediated inhibition of JNK signaling in hepatocytes.
Experimental animal models of liver disease
TNFa, FasL, and other ligands of the so-called death receptors (DRs) have been implicated in the induction of hepatocyte death, but the molecular basis of the pathways controlling death remain unclear (Wullaert et al., 2007; Malhi and Gores, 2008) . Hepatocyte death induced by TNFa is implicated in several human liver conditions including hepatitis, alcoholic liver disease, acute liver failure, I/R injury, liver graft rejection and HCC (Streetz et al., 2000) . The distinct mechanisms regulated by TNFa have been evaluated in different animal models of liver injury.
Animal models of hepatitis
TNFa plays a prominent role in the pathogenesis of chronic hepatitis B (HBV) and C viral (HCV) infection (Sun and Karin, 2008) . Indeed, HBV-infected patients had Following Kupffer cell activation, TNFa is released and binds to TNF-R1 exposed on hepatocytes, with consequent assembling of Complex I. This complex is essential for signaling activation of the NF-kB and JNK cascades. NF-kB activity promotes the activation of genes such as Gadd45b and A20. These genes block TNFa-induced hepatocyte death using two distinct mechanisms.
higher plasma levels of TNFa and their peripheral blood mononuclear cells exhibited higher TNFa production in vitro (Gonzá lez-Amaro et al., 1994) . Injection of either TNFa or lipopolysaccharide (LPS) in mice reproduces the pathogenesis of HBV and HCV infection (Kushner, 1982; Pfeffer et al., 1993) . LPS induces TNFa production by macrophages (Beutler et al., 1985) . Although TNFa and LPS alone do not cause severe liver toxicity when injected in healthy mice, co-administration with GalN, a hepatotoxin that blocks transcription specifically in hepatocytes, drastically sensitizes mice to TNFa-mediated hepatotoxicity and lethality. Indeed, treatment with either TNFa/GalN or LPS/GalN induces hepatitis with higher serum AST/ALT levels, T-cell infiltration, massive granulocyte accumulation and hepatocyte death (Kushner, 1982) . Injection of LPS/GalN also mediates (directly or indirectly) many of the clinical manifestations of alcoholic hepatitis (Hill and McClain, 2004) and fulminant liver failure (Tsuji et al., 1997) .
Administration of the T-cell mitogen concanavalin A (ConA) also results in massive hepatitis associated with acute liver failure. The pathogenesis of this hepatitis involves T-cells and various cytokines, including TNFa, and reproduces several aspects of viral and autoimmune hepatitis in humans (Tiegs et al., 1992) .
Models of liver regeneration
Wound repair activity in the liver is associated with an orchestrated cellular response leading to tissue regeneration, which involves coordinated cell activation and proliferation ( Figure 1) (Fausto et al., 2006; Michalopoulos, 2007) . Liver regeneration is a process that normally does not rely on stem cells or liver cell progenitors, but rather on mitotic division of pre-existing differentiated liver cells, including hepatocytes, bile duct epithelium and endothelial cells (Michalopoulos, 2007) . The ability of the adult liver to restore its mass and function after tissue removal is a unique property of this organ. One of the most extensively characterized model systems for studying liver regeneration is partial hepatectomy (PH), consisting of surgical tissue removal in rodents (Fausto et al., 2006; Michalopoulos, 2007) . For instance, the left and medial lobes of the liver can be excised, resulting in removal of 70% of the hepatic mass. PH triggers a sequence of events that proceeds in an orderly fashion and can be observed from the first minutes up to 5-7 days following surgical removal (Fausto et al., 2006; Michalopoulos, 2007) . Hepatocytes are the primary cells that enter the cell cycle. The process is highly regulated and controlled by growth factors and cytokines that activate signaling pathways such as the mitogen-activated protein kinases (MAPKs) and nuclear transcription factors pathways (Fausto et al., 2006) . TNFa seems to play a dominant role in regulating hepatocyte survival during liver regeneration, but might also promote hepatocyte proliferation (Yamada et al., 1997) .
Models of HCC
The loss of hepatic mass due to liver injury activates the proliferation of hepatocytes that might provide a promoting environment for tumor formation. HCC rarely develops in the absence of hepatitis, fibrosis and cirrhosis (Thorgeirsson and Grisham, 2002) . Indeed, it was shown that the interaction of hepatocytes with inflam-matory cells results in an altered microenvironment that appears to be crucial both in the early and late stages of carcinogenesis. Hepatic carcinogenesis, however, is a complicated process and despite extensive investigation the molecular events that regulate the entire process are still largely unknown (Hussain and Harris, 2007) .
The mdr2 knockout mouse represents an interesting model of HCC. Mice lacking the mdr2 gene fail to transport phosphatidyl choline into the bile, with consequent accumulation of phospholipids in hepatocytes. This accumulation causes TNFa-mediated hepatitis and severe inflammation, which gradually progress in formation of neoplastic nodules at approximately 6 months and tumor development at approximately 18 months (Mauad et al., 1994) .
Diethylnitrosamine (DEN) is a chemical commonly used to induce HCC in rodents because it causes degenerative, proliferative and neoplastic lesions in the liver (Pound et al., 1973) . DEN administration also leads to rapid accumulation of TNFa . Although the mechanisms by which DEN induces TNFa are not clear, release of this cytokine plays a crucial role in the carcinogenetic process (Karin, 2006) . Treatments with DEN primarily affect the liver tissue, where it is converted by P450-dependent mono-oxygenase into highly reactive molecules. These electrophilic DEN species bind covalently to multiple sites on DNA, proteins and other cell constituents, inducing DNA damage and mutations that cause hepatocyte death and successive compensatory proliferation (Cayama et al., 1978; Lim, 2002; Karin, 2006) . In DEN-treated mice, foci of altered hepatocytes are observed at 4-5 months of age, and by 8 months malignant (macroscopic) nodules become visible. These events are considered early steps responsible for the initiation and promotion of hepatocarcinogenesis, as indicated by the eventual appearance of malignant tumors (Cayama et al., 1978; Karin, 2006) .
TNFa pathway
Liver homeostasis involves a balance between hepatocyte death and survival (Wullaert et al., 2007) . Excessive hepatocyte death contributes to liver injury, whereas hepatocyte survival and protection are crucial elements for liver cancer development (Figure 1) (Karin, 2006; Wullaert et al., 2007) . The proinflammatory cytokine TNFa plays a pivotal role in liver homeostasis because it has the ability to promote both hepatocyte death and survival (Schwabe and Brenner, 2006; Wullaert et al., 2006) .
TNFa can exert a variety of biological effects that are mediated by its engagement of TNF-receptor 1 (TNF-R1) and TNF-R2. Whereas soluble TNFa efficiently activates TNF-R1 signaling, activation of TNF-R2 signaling requires the binding of membrane-bound TNFa. Both receptors lack intrinsic enzyme activity; thus, signaling by TNF-R1 and TNF-R2 is achieved by recruitment of adaptor proteins that bind to their cytosolic region (Wajant et al., 2003) . For instance, on binding of the ligand, the intracellular region of TNF-R1 forms a homotrimer that interacts with TNF-R-associated death domain (TRADD). This recruitment is mediated by a direct interaction of the death domain, a conserved protein-protein interaction motif of 80 aa contained in all DRs. TNF-R1-bound TRADD is then able to engage downstream adaptors, such as TNFa receptor-associated factor (TRAF)2 and receptor-interacting protein kinase (RIP), which together form the so-called complex I. Assembly of this complex is essential to signal the activation of NF-kB, as well as the JNK cascade ( Figure 2 ) (Wajant et al., 2003; Papa et al., 2006) . Numerous studies have provided evidence that NF-kB induces the activation of survival effectors in the context of TNFa-induced signaling in the liver (Streetz et al., 2000; Schwabe and Brenner, 2006; Wullaert et al., 2007) . This process is believed to involve the transcriptional expression of cytoprotective genes (Dutta et al., 2006) . In contrast, activation of JNK signaling in the liver has been associated with promotion of cell death (discussed below) (Varfolomeev and Ashkenazi, 2004; Papa et al., 2006; Wullaert et al., 2006) .
Besides activating the NF-kB and JNK pathways, TNF-R1 can activate caspase proteolysis. This activation occurs when the cytosolic region of TNF-R1 is released from the membrane and recruits procaspase-8 and FADD to form complex II, which results in activation of caspase-8. Active caspase-8 then proteolytically cleaves several effector caspases that are responsible for apoptosis. In addition to activation of the downstream executioner caspases, hepatocytes require a second pathway that involves mitochondrial amplification of signals to undergo cell death. It should be noted that caspase-dependent cell death is enhanced by activation of JNK signaling (Wajant et al., 2003) . Below we discuss the mechanisms and molecules involved in TNFa-mediated signaling.
TNFa-induced NF-kB signaling
The evolutionarily conserved nuclear transcription factor NF-kB plays a crucial role in development, inflammation, immune responses, and cell survival (Hayden and Ghosh, 2004; Dutta et al., 2006) . Stimulation of TNF-R1 by TNFa represents a prototype model of NF-kB activation. NFkB represents a family of dimeric transcription factors that recognize a common DNA motif called the kB motif. The dominant form of NF-kB in most cells is a heterodimer of the p50 and p65 (alternatively called RelA) subunits. Inhibitory IkB proteins normally sequester NF-kB complex in the cytoplasm by direct interaction. TNFainduced signals lead to activation of the upstream IkB kinase (IKK) complex, which consists of two catalytic subunits IKKa/IKK1 and IKKb/IKK2 and the subunit IKKg/NEMO. Cells stimulated with TNFa rapidly activate the IKK complex. IKKb-mediated phosphorylation of IkBa then leads to its poly-ubiquitination and subsequent proteolytic degradation, allowing NF-kB translocation into the nucleus and regulation of the transcription of target genes (Hayden and Ghosh, 2004; Dutta et al., 2006) .
Numerous studies have provided evidence that NF-kB mediates pro-survival signals in the liver in the context of DR stimulation. NF-kB-dependent signals involve the transcriptional activation of pro-survival genes (Hayden and Ghosh, 2004; Dutta et al., 2006) . Among these genes are the caspase-8 inhibitor c-FLIP, members of the Bcl-2 family, Bcl-xL and A1/Bfl-1, and the cellular inhibitors of apoptosis (c-IAPs) and the X-liked inhibitor of apoptosis (XIAP). Whereas c-FLIP acts at the receptor level in the DR-induced apoptotic pathway by competing with caspase-8 for binding to complex II, Bcl-xL and A1/Bfl-1 act at the level of mitochondria, where they prevent tBid-induced mitochondrial depolarization and the release of cytochrome c into the cytosol. A mechanism suggested for c-IAPs-mediated suppression of apoptosis appears to be through direct inhibition of caspases. In this mechanism, c-IAPs directly bind to and inhibit effector caspases such as caspase-3 and caspase-7 and indirectly prevent activation of caspase-6 and caspase-9. Overexpression of each of these genes in NF-kB-deficient cells, however, can only provide partial protection against TNFa-induced apoptosis, suggesting that additional NF-kB-dependent protective mechanisms exist (Dutta et al., 2006) . It has recently been proposed that NF-kB-dependent pro-survival activity is directly linked to suppression of the JNK pathway. Two studies in 2001 initially described the protective cross-talk between the NF-kB and JNK pathways (De Smaele et al., 2001; Tang et al., 2001 ). More recent studies have shown that the liver provides a paradigm for the cross-talk between these two pathways, as discussed below.
Mechanisms for the TNFa-induced JNK cascade
MAPKs regulate several critical cellular functions in addition to cell death, including cell proliferation and differentiation (Davis, 2000) . Signal specificity is provided in part by the existence of multiple signaling MAPKs. Extracellular signals are orchestrated via cascades of sequential phosphorylation by their upstream activators. MAPKs are activated by upstream MAPK kinases (MAP2Ks), which in turn are activated by MAP2K kinases (MAP3Ks) (Davis, 2000) .
JNKs are a group of serine/threonine protein MAPKs that, together with p38 MAPKs and extracellular signalregulated kinases (ERKs), mediate cellular responses through interaction with and phosphorylation of downstream targets. Once activated, these pathways can lead to selective activation of different types of transcription factors, ultimately regulating a myriad of biological functions, including inflammation, stress responses, cell survival and cell differentiation. For instance, the JNK and p38 cascades mostly mediate activation of members of the transcription factor AP-1, a heterodimeric complex composed of proteins of the Jun, Fos, Maf and ATF subgroups. MAPKs, however, also have biological effects that are independent of their activity as transcriptional regulators (Davis, 2000; Johnson and Lapadat, 2002) .
At least six protein kinases function as MAP2Ks: MEK1 and MEK2, phosphorylating ERKs; MKK3 and MKK6, phosphorylating p38s; and MKK4 and MKK7, phosphorylating JNKs. It is worth noting that activation of each protein kinase strictly depends on the stimulus and cell type in which it is activated. In the context of the JNK pathway, MKK4 is primarily activated by stress, whereas MKK7 is activated by both inflammatory cytokines, such as TNFa, and stress. Interestingly, MKK4 might also phosphorylate p38, suggesting that it can also regulate the p38 pathway in the same tissue (Davis, 2000; Johnson and Lapadat, 2002) .
Regulation of molecules in the MAP3K family is more complex. For instance, in the context of TNF-R1, previous studies have shown that TNFa-induced activation of JNK (and p38) is mediated by recruitment to TNF-R1 of the adaptor TRAF-2 and subsequent activation of four major MAP3K groups: the MEKK group (MEKK1/2/3/4), the MLK group (MLK1/2/3, DLK, and LZK), the ASK group (ASK1 and ASK2) and TAK1. Many of these MAP3Ks, however, can activate more than one MAPK pathway and can also trigger activation of the NF-kB pathway, highlighting the complexity of this signaling (Davis, 2000) .
Oxidative stress can also partly activate MAPK pathways, in particular the p38 and JNK pathways. This condition occurs when the levels of reactive oxygen species (ROS) in cells exceed the capacity of antioxidant factors to limit their accumulation. In response to certain stress stimuli and cytokines (including TNFa), ROS formation and accumulation above a certain threshold can induce cell damage. This is, in fact, a common mechanism in liver injury. However, the precise mechanism(s) by which ROS trigger cell damage is unclear. It has been proposed that, in some circumstances, ROS cytotoxicity involves inhibition of NF-kB activity . In addition, it is becoming increasingly clear that in other systems this cytotoxicity is mediated in part by JNK activation. Recent studies by Karin and colleagues, for instance, revealed that TNFa-induced ROS oxidize and inactivate the MAPK phosphatases (MKPs) such as MKP-1, MKP-3, MKP-5 and MKP-7 that are known to dephosphorylate MAPKs (Karin and Gallagher, 2005; Kamata et al., 2005) . Another study revealed that ROS also prompt the induction of ASK1 (Matsuzawa and Ichijo, 2008) . It was shown that ask1 -/-mouse embryonic fibroblast (MEF) cells exhibit a defect in the induction of JNK signaling and cell death following stimulation of TNF-R1 (Matsuzawa and Ichijo, 2008) . Hence, ROS might influence activation of the JNK pathway downstream of TNF-Rs by both inducing MAP3Ks and inhibiting MKPs. The relative importance of each of these mechanisms to sustained induction of TNF-R signaling is likely to depend on the tissue and biological context.
Role of NF-kB in health and liver disease NF-kB in embryonic liver development
NF-kB signaling plays a key role in liver physiology and development (Hayden and Ghosh, 2004; Dutta et al., 2006) . RelA-deficient mice provided the first evidence that NF-kB regulates embryonic liver homeostasis. Disruption of the RelA gene locus leads to embryonic lethality at mid-gestation and this lethality is associated with massive induction of PCD in the liver (Beg et al., 1995) . Further studies showed that RelA is not critical for liver development but might serve as a vital protective function against TNF-R1-induced PCD. Indeed, mice harboring compound mutation of RelA and TNF-R1 (relA -/-/ tnfR1 -/-) survived during embryonic development and exhibited normal liver morphology at birth, but most animals developed acute hepatitis soon after and died around 10 days of age (Rosenfeld et al., 2000) . The lethality phenotype in embryos of relA -/-mice has also been detected in mice lacking either IKKb or IKKg, two subunits of the IKK complex (Li et al., 1999a,b; Makris et al., 2000; Rosenfeld et al., 2000) .
NF-kB protects against liver injury
Numerous studies have now confirmed the pivotal role that NF-kB plays in preventing TNFa-mediated PCD in adult hepatocytes. Karin and collaborators showed that hepatocyte-specific deletion of IKKb (IKKbDHep) sensitizes mice to liver failure and apoptosis following ConA administration (Maeda et al., 2003) . IKKbDHep mice, however, are apparently otherwise healthy and fertile, with normal postnatal liver development and function. Indeed, LPS administration induced a similar degree of liver damage in IKKbDHep and wild-type mice (Maeda et al., 2003) . Consistent with these findings, Trautwein and colleagues recently found that injected TNFa or challenge with LPS does not sensitize the liver of either IKKbDHep or another mouse model, IKKb f/f -Mx-Cre, which exhibited efficient knockout of IKKb in Kupffer, non-parenchymal and lymphoid cells after Cre-mediated recombination (Luedde et al., 2005) . A possible explanation for the selective role of IKKb and NF-kB in liver protection against ConA-induced apoptosis is that this agent induces membrane-bound TNFa expression by cells, which can then activate both TNF-R1 and TNF-R2 in hepatocytes. In contrast, LPS/TNFa-mediated apoptosis is dependent on soluble TNFa, which can only activate TNF-R1. As a consequence, ConA-challenged IKKbDHep mice exhibit more robust and prolonged JNK activation than mutants treated with LPS. Indeed, inhibition of JNK results in a reduction in ConA-induced liver damage, demonstrating that the primary mechanisms by which IKKb-dependent NF-kB activation prevents TNFainduced apoptosis in vivo is through attenuation of JNK activation (discussed below) (Maeda et al., 2003; Wullaert et al., 2007) . Another study showed that hepatocyte-specific deletion of IKKb does not lead to increased apoptosis on challenge with ConA, which is in sharp contrast with previous results (Luedde et al., 2005) . However, activation of NF-kB signaling after pharmacological inhibition of IKKb was not impaired after TNFa stimulation. The authors concluded that activation of NF-kB in the adult liver induced by TNFa could occur independently of IKKb. However, it has been shown that IKKbDHep mice are resistant to hepatic I/R injury, mimicking events that can occur during organ transplantation, tissue resection and hemorrhagic shock in humans. Conversely, pharmacological inhibition of IKKb was shown to prevent hepatic I/R injury (Luedde et al., 2005) . Together, these results support the notion that different IKK subunits can mediate differential functions in the adult liver.
Hepatocyte-specific deletion of the IKKg gene (IKKgDHep) renders mice highly susceptible to LPSinduced injury with massive hepatocyte apoptosis (Luedde et al., 2005) . However, in a mouse model of IKKg f/f -Mx-Cre, which exhibited efficient knockout of IKKg in both myeloid and non-parenchymal cells after Cre-mediated recombination, challenge with TNFa caused a higher degree of liver injury, promoting both apoptotic and necrotic PCD. These findings are consistent with the notion that deletion of IKKg completely abolishes activation of NF-kB; in contrast, IKKb deletion only partially inhibits this activation because of the redundant function of IKKa activity (Luedde et al., 2005; Wullaert et al., 2007) .
Whether or not NF-kB activation depends on IKKb, the data presented here together indicate that NF-kB activity plays a protective role to prevent TNFa-induced cell death in the adult liver. These conclusions are also in agreement with a recent study that showed that genetic inactivation of RelA in hepatocytes sensitizes mice to cytotoxicity induced by treatment with either LPS or TNFa (Geisler et al., 2007) . Clinical evidence also supports this view. NF-kB is activated in the livers of subjects with chronic hepatitis C and expression of RelA in these livers is associated with a lower degree of apoptosis and slower progression to fibrosis-associated cirrhosis (Boya et al., 2001) . Likewise, RelA expression is suppressed in pregnant women with chronic hepatitis E (HEV) infection and correlates with the severe liver damage and high mortality observed in these patients (Prusty et al., 2007) .
NF-kB in liver regeneration
Hepatocytes have a remarkable proliferative capacity but are quiescent in healthy liver. Liver regeneration after PH provides a fundamental paradigm for the liver response to injury (Fausto et al., 2006; Michalopoulos, 2007) . NFkB is one of the transcription factors that protect cells from undergoing apoptosis in a wide range of cell types, including hepatocytes (Fausto et al., 2006) . After PH, NFkB is rapidly activated and both protects hepatocytes from apoptosis and promotes hepatocyte proliferation. Although the factors responsible for NF-kB induction during liver regeneration are still under investigation, a likely candidate is TNFa itself (Schwabe and Brenner, 2006) . Expression of this cytokine is induced during liver regeneration (Evan et al., 1995) and neutralizing antiTNFa antibodies can inhibit hepatocyte DNA synthesis during this process (Akerman et al., 1992) . Furthermore, NF-kB activity is markedly impaired in TNF-R1 knockout mice after PH challenge (Yamada et al., 1997) . Moreover, infection with adenovirus expressing the super-repressor IkBa (IkBa-S), which blocks NF-kB activity, results in induction of massive apoptosis (Iimuro et al., 1998) . Similar effects were obtained using pharmacological inhibitors of NF-kB activity (Cressman et al., 1994; Plumpe et al., 2000) . Whereas initial studies using adenoviral IkBa-S delivery implicated NF-kB in hepatocyte survival and proliferation after PH (Iimuro et al., 1998) , subsequent studies demonstrated that hepatocyte-specific IkBa-S expression has no adverse effect on these processes (Chaisson et al., 2002) . There is still controversy regarding which liver cell types are primarily affected by NF-kB during regeneration. It has been reported that PH induces NF-kB activation primarily in Kupffer cells, where it promotes the synthesis of factors that stimulate hepatocyte growth (Chaisson et al., 2002; Abshagen et al., 2007) . Other studies suggested a role for NF-kB activation in hepatocytes during regeneration (Wullaert et al., 2007) . Support for these roles comes from other models of compensatory hepatocyte growth, which showed that activation of NF-kB in hepatocytes induces protective genes that antagonize TNFa-mediated PCD (discussed below) Luedde et al., 2007) . Additional studies have shed further light on the reasons for discrepancies between earlier conclusions. Trautwein and collaborators reported that IKKb deletion in hepatocytes accelerates hepatocyte proliferation after PH (Malato et al., 2008) . Therefore, taken together, studies in the literature support the notion that NF-kB plays important roles in liver regeneration both in hepatocytes and non-parenchymal cells.
NF-kB in liver carcinogenesis
Tumor development involves an imbalance between cell proliferation and cell death (Karin, 2006; Wullaert et al., 2007) . Given the prominent role of NF-kB in the control of liver cell proliferation and cell death, it would be logical to expect that NF-kB is involved in both the initiation and development of liver cancer (Karin, 2006) . Evidence of the participation of NF-kB in carcinogenesis has indeed recently become more apparent. Studies in animal models highlight the fundamental role of the NF-kB pathway in the regulation of PCD and proliferation in hepatocytes that, when deregulated, might contribute to the onset of HCC.
The first evidence of NF-kB in hepatocarcinogenesis in an animal model came from analyses of Mdr2 knockout mice, a model of inflammation-driven HCC. A study by Pikarsky and colleagues demonstrated that hepatocytes adjacent to regions of inflammation in this model express high levels of nuclear NF-kB. It was also shown that NFkB protects transformed hepatocytes from PCD through upregulation of pro-survival genes. These and other data suggested that NF-kB is a tumor-promoting factor in hepatocytes (Pikarsky et al., 2004) . However, another recent study using the DEN-induced HCC model showed that hepatocyte-specific deletion of IKKb markedly increases hepatocarcinogenesis, whereas deletion of IKKb in both hepatocytes and hematopoietic-derived cells inhibits this process. These results support a model whereby lower activation of NF-kB augments hepatocyte death in the form of necrosis, releasing products that induce the secretion of pro-inflammatory cytokines (i.e., TNFa) from myeloid cells and stimulating compensatory proliferation of surviving DNA-damaged hepatocytes Sakurai et al., 2008) (Figure 1) . The compensatory proliferation of NF-kB-deficient hepatocytes in response to DEN treatment plays a key role in the development of liver cancer. Thus, whereas NF-kB plays an inhibitory role in hepatocytes, it promotes hepatocarcinogenesis in Kupffer cells. A growth-suppressing role for IKKb in hepatocytes during liver regeneration was also suggested by studies showing that extracellular matrix, basement membrane, and expression of integrins were increased in IKKbDHep mice (Koch et al., 2009 ). These findings were recently supported by other studies that showed that conditional IKKg deletion in hepatocytes causes steatohepatitis and HCC, suggesting a tumor-suppressor role for NF-kB activity (Luedde et al., 2007) . On the other hand, transgenic mice in which a constitutively active form of IKKb was expressed in hepatocytes showed that NF-kB activation in these cells did not significantly affect DEN-induced HCC initiation (Yau et al., 2009) .
It has been suggested that, like NF-kB, the p38a MAPK also suppresses DEN-induced cancer development in the liver. It was shown that, using distinct mechanisms, NF-kB and p38a cooperate to prevent ROS accumulation, which promotes the necrotic cell death that drives compensatory proliferation during this process (Sakurai et al., 2008) .
Because of these seemingly conflicting results in different models of HCC, it remains unclear whether NF-kB activity in hepatocytes is important for carcinogenesis. It is worth mentioning that this might depend on differences in the specific mouse model used (Vainer et al., 2008) . Given that HCC develops in the settings of inflammation-driven cancer associated with challenge with hepatitis virus and chronic alcoholism, it would be appropriate to obtain further data in these and other animal models or in humans. For instance, rather than using chemical hepatocarcinogenic compounds, more emphasis should be placed on developing mouse models that resemble viral hepatitis infection and alcohol consumption, which are the major agents causing HCC in humans. Another important challenge will be to delineate the mechanisms and the critical checkpoints that control hepatocyte death and proliferation in HCC.
NF-kB inhibits JNK-mediated cell injury and death
The cross-talk between NF-kB and JNK in antagonism of TNF-R1-induced PCD has probably been more thoroughly documented in the liver than in all other tissues. Indeed, much work has been done to elucidate the mechanisms behind the protective activity of NF-kB against TNFa-mediated injury in the liver. It is now accepted that cross-talk between NF-kB and JNK activity is a major determinant in the fate of hepatocytes during TNFa challenge (Schwabe and Brenner, 2006) . One of the mechanisms through which NF-kB provides its survival signals in TNFa-induced cell death is inhibition of the prolonged activation of JNK. Blocking of NF-kB by ablation of either RelA or IKKb or by expression of IkBa-S impairs the shutdown of TNFa-induced JNK signaling. Interestingly, it is the persistent rather than the transient activation of JNK that is ultimately responsible for triggering death. Thus, NF-kB-mediated suppression of this prolonged activation is crucial for inhibition of TNFa-induced cell death (De Smaele et al., 2001; Tang et al., 2001; Papa et al., 2004a) .
Analyses of IKKb/JNK1 double mutants showed that the absence of JNK1, one of the two major JNK isoforms expressed in the liver, delays embryonic mouse lethality caused by compromised NF-kB activation, suggesting that JNK signaling is an important mediator of apoptosis in the liver during embryogenesis and that suppression of this signaling is a key mechanism by which NF-kB promotes survival during liver development . Evidence of the protective cross-talk between NF-kB and JNK also comes from analyses of adult livers with defects in NF-kB activation. The proapoptotic effects of ConA-induced hepatitis are increased in IKKb-deficient hepatocytes and are correlated with persistent activation of JNK. Treatment of IKKbDHep primary cells with a small-molecule inhibitor of JNK (SP600125) results in inhibition of TNFa-induced cell death (Maeda et al., 2003) . Likewise, ConA-challenged (but not LPS-challenged) IKKbDHep mice exhibit more robust and prolonged JNK activation than similarly treated control mice, demonstrating that prolonged JNK activation is necessary for both TNF-R1-and TNF-R2-mediated liver injury (Maeda et al., 2003) . Similar results were obtained with RelA-deficient mice, in which intravenous injection of either murine or human TNFa promoted prolonged JNK activation in hepatocytes. Treatment of primary cultures of RelA-deficient hepatocytes with SP600125 reduced the ability of TNFa to induce hepatocyte death. The authors of these studies, however, questioned whether prolonged JNK activation is mediated only in systems in which TNFa-inflicted cytotoxicity is dependent on both TNF-R1 and TNF-R2, as observed only in ConA-induced liver injury (Geisler et al., 2007) .
Other than in hepatitis models, the interplay between NF-kB and JNK has been extensively investigated in mouse models in which tissue injury triggers compensatory proliferation. Ben-Neriah and colleagues suggested that specific inhibition of NF-kB in hepatocytes of mdr2 -/-mice augments JNK activation at 7 months of age, the time at which premalignant changes began to occur. The increase in JNK activation in this model was dependent on continuous release of TNFa, because mdr2 -/-mice challenged with anti-TNFa antibodies showed suppressed JNK activation and c-Jun expression in the liver (Pikarsky et al., 2004) . Similar results were obtained in the model of DEN-induced HCC. Hepatocyte deletion of IKKb augments DEN-induced JNK activation and hepatocarcinogenesis. Generation of double mutant mice harboring specific inhibition of both IKKb and JNK1 (IKKbDHep/jnk1 -/-) provided further evidence of the dependence of hepatocyte death on JNKs. Indeed, JNK1 deletion reversed increased hepatocyte death and the susceptibility of mice to HCC progression in the absence of IKKb (Sakurai et al., 2006) . Consistent with these findings, recent studies in jnk1 -/-and jnk2 -/-mice challenged with DEN revealed that the JNK1 pathway has a dual stage-dependent function in HCC: one in the early stages of carcinogenesis in mediating DEN-induced PCD and the other in late stages, when it promotes the compensatory proliferation of hepatocytes, which supports the formation of liver cancer (Hui et al., 2008) .
It was suggested that ROS induced by TNFa are responsible for prolonged JNK activation (Sakon et al., 2003) . Whereas NF-kB inhibits JNK-mediated PCD, ROS accumulation induces JNK-mediated PCD. Indeed, pretreatment with the antioxidant butylated hydroxyanisole protects mice from ConA-induced liver failure, a response that requires sustained JNK activation . Like NF-kB, p38 suppresses JNK activation (Sakurai et al., 2008; Heinrichsdorff et al., 2008) . However, it is not known whether this suppression of JNK by p38 is also involved in inhibition of TNFa-mediated liver injury.
Mechanisms of JNK-mediated liver injury
The exact mechanisms through which JNK activation promotes TNFa-induced apoptosis are unknown. It was initially suggested that JNKs act at a level upstream of caspase-8 through generation of a novel Bid cleavage product, jBid (Deng et al., 2003) . However, this needs to be confirmed in animal models, including models of liver injury. Analyses of jnk1 -/-and jnk2 -/-mice challenged with either LPS/GalN or ConA/GalN suggest that Bid activation is independent of JNK activity, indicating a parallel role for Bid and JNK signaling in mediating TNFainduced liver injury (Ni et al., 2009) .
Other studies suggest that activated JNK in IKKbDHep livers after challenge with ConA sequentially phosphorylates and activates the ubiquitin ligase, Itch. Once activated, Itch promotes the degradation of c-FLIP and TNFa-induced PCD . However, it is not clear whether the enhanced proteasomal turnover of c-FLIP represents a general mechanism that is required for TNFa-induced PCD in hepatocytes. For instance, abrogation of the NF-kB response in RelA-deficient hepatocytes leads to prolonged JNK activation after TNFa challenge in vivo. However, c-FLIP degradation was detected in this system before the onset of morphologic signs of JNK-mediated apoptosis, raising doubts regarding the interpretation that c-FLIP degradation is reduced as a consequence of JNK-mediated phosphorylation of Itch (Geisler et al., 2007) . Indeed, the authors suggested that prolonged JNK activation in NF-kB-deficient hepatocytes might not mediate cell death only through an Itch/c-FLIP pathway, but also through another target upstream of mitochondria, more likely at the level of caspase-8 activation (Geisler et al., 2007) . In support of this view, it was recently shown that JNK contributes to TNF-R1-induced PCD signaling in hepatocytes by activating another proapoptotic BH3-only protein, Bim, rather than Bid. Combined loss of Bid and Bim rendered mice more resistant to induction of hepatitis after challenge with LPS/GalN. Injection of the JNK inhibitor D-JNKI1 reduced LPS/GalN-induced hepatitis in bid -/-but not in bim -/-mice (Kaufmann et al., 2009 ). Activation of JNK signaling is also required for TNFa expression by hematopoietic cells, which it is necessary for promoting ConA-induced hepatitis (Das et al., 2009 ). This study, however, also showed that JNK is not required for TNFa-stimulated PCD during the development of hepatitis, which appears to be in conflict with findings in other recent studies (Maeda et al., 2003; Chang et al., 2006; Wang et al., 2006; Kodama et al., 2009 ). Indeed, although there is controversy over whether the two hepatic JNK isoforms JNK1 and JNK2 have specialized functions in cell survival, growth and PCD, knockout studies have shown that JNK activation contributes to TNF-R-mediated hepatic death (Maeda et al., 2003; Chang et al., 2006; Wang et al., 2006; Kodama et al., 2009) .
JNK-mediated apoptosis has also been documented in the activation of Fas and TNF-associated apoptosisinducing ligand (TRAIL) DRs in hepatocytes. Higher hepatic bile acid concentrations facilitate Fas and TRAIL activation (Higuchi and Gores, 2003) . Hä ussinger and colleagues investigated whether activation of NADPH oxidase is responsible for bile acid-induced ROS production, which accounts for the activation of JNK signaling (Reinehr et al., 2005) . However the molecular mechanisms leading to activation of such signaling and its contribution to the final apoptotic event are not fully understood.
Mechanisms of NF-kB-mediated suppression of JNK signaling
Interplay between NF-kB and JNK signaling can also occur at the transcriptional level (Papa et al., 2004a . To date, at least three NF-kB-dependent genes have been identified as potential candidates for NF-kBmediated control of TNFa-induced JNK activation: growth arrest DNA damage-inducible gene 45b (Gadd45b), X-linked inhibitor of apoptosis (XIAP), and the zinc finger protein A20. As discussed below, although Gadd45b seems to have a crucial role in protection against JNK-induced hepatocyte death in the PH model, the roles of XIAP and A20 in vivo in the context of TNFa signaling remain to be delineated. Indeed, whereas A20 seems to protect mice against LPS/GalN-induced hepatocyte apoptosis, it is not yet known whether this protective function is mediated by inhibition of JNK ( Figure  2 ) (Wullaert et al., 2007) .
With regard to the in vivo role of Gadd45b in cytoprotection, Gadd45b-mediated inhibition of JNK activity appears to involve blockade of MKK7 (Papa et al., 2008) . Gadd45b directly associates with MKK7, blocking its catalytic activity and precluding access of ATP to its catalytic pocket (Papa et al., 2004b (Papa et al., , 2007 . Early studies suggested that Gadd45b is not involved in the NF-kBmediated control of TNFa-induced PCD, because gadd45b -/-MEF cells had no defects in the suppression of JNK induction or PCD downstream of TNF-Rs (Amanullah et al., 2003) . Thus, the role of Gadd45b in cytoprotection against TNFa-mediated JNK activation might be tissue-and context-dependent.
With regard to liver injury, we recently reported that Gadd45b is important for hepatocyte protection during liver regeneration. Whereas wild-type mice fully recovered from surgery, the survival rate of gadd45b -/-mice was dramatically reduced. Analyses of livers from these mice revealed that loss of Gadd45b is associated with liver injury. In contrast, wild-type mice showed no signs of this injury. gadd45b -/-livers also exhibited reduced hepatocyte proliferation after PH, but it is likely that this reduction is partly a secondary consequence of an increase in PCD in gadd45b -/-mice. Significantly, PCD induction in gadd45b -/-mice during liver regeneration is associated with augmented JNK activation, which correlates with increased caspase activation in gadd45b -/-livers (Papa et al., 2008) . Given the crucial role of TNFa in liver regeneration, these findings are consistent with a model in which TNFa stimulates NF-kB activity in hepatocytes following PH (Figure 2 ). Transcriptional activity of NF-kB upregulates the expression of Gadd45b, which in turn binds to and specifically blocks MKK7-JNK activity. Indeed, double mutant mice harboring compound deletion of Jnk2 and Gadd45b (gadd45b -/-/jnk2 -/-) exhibit reduced hepatocyte death and increased proliferation. Although the data provide support for the notion that Gadd45b promotes hepatocyte survival during liver regeneration by modulating JNK-mediated PCD, the role of Gadd45b in liver protection against TNFa-mediated injury in models of TNF-R-mediated liver challenge is uncertain. In fact, it is likely that Gadd45b protects the liver during challenges in which activation of JNK is independent of ROS production. Indeed, using a model of ConA-induced hepatitis, in which JNK activation is dependent on ROS, Gadd45b does not seem to be required for inhibition of JNK activation. However, in models such as PH, in which JNK activation does not rely on induction of ROS, Gadd45b can mediate the protective activity of NF-kB in blocking TNFa-induced, JNK-mediated PCD (Papa et al., 2008) (Figure 2 ).
Concluding remarks
Growing evidences indicate that programmed cell death regulates different physiological and pathological conditions (Guicciardi and Gores, 2005) . As outlined here, the liver offers a paradigm example of how cell death can be detrimental for the entire organism, because it has been associated with the onset of liver disease (Karin, 2006; Wullaert et al., 2007; Sun and Karin, 2008) . Although there are no effective treatments for many liver disorders, our recent findings support possible steps forward (Papa et al., 2008) . Much work has been done to further our understanding of the mechanisms of liver disease. Among these, NF-kB and JNK signaling represent important elements in liver pathology (Wullaert et al., 2007; Sun and Karin, 2008) . Taken together, the studies reported here demonstrate that NF-kB activation is important for sustaining hepatocyte survival during TNFa-mediated chronic liver injury through inhibition of the JNK pathway. However, the pro-survival activity of NF-kB could also play a detrimental role because it might enhance HCC progression (especially in the late stages of carcinogenesis), in part by enhancing the survival of transformed hepatocytes, indicating that NF-kB signaling is a problematic therapeutic target.
Because the NF-kB pathway has a pivotal role in inflammatory response, blockers of this pathway are currently used for treatment of inflammatory liver conditions. Drugs that target NF-kB activity, however, can alleviate the inflammatory response, but at the same time might cause increased hepatocyte death because of the prosurvival activity of NF-kB (Sun and Karin, 2008) . Therefore, more work is necessary to unravel the proteins under transcriptional regulation by NF-kB that mediate the biological function of this transcription factor in specific pathological settings, including liver cancer. Indeed, inhibition of NF-kB activity might be achieved by targeting individual downstream effectors. Specifically, there is a need to develop agents for selective blockade of the pro-survival action of NF-kB without significantly compromising its capacity to serve in immunity and development. Such a selective blockade could help to limit the side effects associated with global inhibitors of the NF-kB pathway.
Gadd45b might represent a promising target. Given that Gadd45b exerts specific and accurate control of JNK signaling during TNF-R-mediated challenge, the Gadd45b-MKK7 interaction might in fact provide a suitable molecular target for devising tools that would not directly impact on NF-kB functions in immunity and development.
